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Abstract
Human mesenchymal stem cells are primary multipotent cells capable of differentiating into several cell types including
adipocytes when cultured under defined in vitro conditions. In the present study we investigated the role of cAMP signaling
and its downstream effectors, protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac) in adipocyte
conversion of human mesenchymal stem cells derived from adipose tissue (hMADS). We show that cAMP signaling
involving the simultaneous activation of both PKA- and Epac-dependent signaling is critical for this process even in the
presence of the strong adipogenic inducers insulin, dexamethasone, and rosiglitazone, thereby clearly distinguishing the
hMADS cells from murine preadipocytes cell lines, where rosiglitazone together with dexamethasone and insulin strongly
promotes adipocyte differentiation. We further show that prostaglandin I2 (PGI2) may fully substitute for the cAMP-elevating
agent isobutylmethylxanthine (IBMX). Moreover, selective activation of Epac-dependent signaling promoted adipocyte
differentiation when the Rho-associated kinase (ROCK) was inhibited. Unlike the case for murine preadipocytes cell lines,
long-chain fatty acids, like arachidonic acid, did not promote adipocyte differentiation of hMADS cells in the absence of a
PPARc agonist. However, prolonged treatment with the synthetic PPARd agonist L165041 promoted adipocyte
differentiation of hMADS cells in the presence of IBMX. Taken together our results emphasize the need for cAMP signaling
in concert with treatment with a PPARc or PPARd agonist to secure efficient adipocyte differentiation of human hMADS
mesenchymal stem cells.
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Introduction
Obesity is a prevalent condition frequently associated with
metabolic disorders such as dyslipidemia, diabetes, hypertension
and cardiovascular diseases. Fat mass excess in severe obesity is
typically not only due to an increase in adipocyte size, but also
adipocyte number [1,2]. In vivo studies in both human and rodents
have illustrated that high fat diets, especially when combined with
carbohydrates, promote both hyperplasic and hypertrophic
development of adipose tissue [3–8]. Of note, results from animal
feeding studies have indicated that the effect of dietary fat on
adipose tissue mass, at least in part, depends on the source and
nature of the fatty acids. Compared to saturated fatty acids, n-3
polyunsaturated fatty acids (PUFAs) have been reported to be less
adipogenic and to prevent excessive growth of adipose tissue in
rodents [9–11]. The effect of n-6 PUFAs on adipogenesis and
obesity has been controversial as n-6 PUFAs, including arachi-
donic acid, have been reported to be both pro- and anti-
adipogenic, both in vitro and in vivo [6,12,13]. However, we have
recently shown that the background diet, in particular the ratio
between carbohydrate and protein, acts on insulin secretion and
cAMP signaling determine the adipogenic action of both n-3 and
n-6 PUFAs, explaining at least in part the apparently discrepant
reports on the effect of PUFA supplementation [6–8,14].
Adipocytes are derived from mesenchymal stem cells (MSCs)
[15] which have the potential to differentiate into several lineages
including adipocytes, osteoblasts, chondroblasts, skeletal muscle
cells and neurocytes [16–18]. Under in vitro conditions, adipocyte
differentiation of MSCs can be induced by a hormonal cocktail
which includes insulin, glucocorticoid and cAMP elevating agents
that together activate several signaling pathways culminating in
the activation of PPARc and terminal adipocyte differentiation
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[15]. Of note, in contrast to murine preadipocytes, differentiation
of human preadipocytes requires the addition of a PPARc agonist
[19].
In addition to PPARc, PPARd and PPARa have also been
implicated in adipocyte differentiation [20–22]. PPARs are
activated by fatty acids and fatty acid-derived metabolites
including leukotrienes, prostaglandins, and lipoxygenase products
[23–27].The n-6 PUFA arachidonic acid has been identified as
one of the main adipogenic fatty acid components of serum [28].
Arachidonic acid can act by direct binding to PPARs, but can also
be converted into various derivatives which stimulate differenti-
ation by activating PPARs [29,30]. Apart from serving as a PPAR
ligand or a ligand precursor, arachidonic acid may promote
adipocyte differentiation via transformation into prostacyclin
(PGI2) that is known to elevate intracellular cAMP levels and
thereby promote terminal differentiation of the two murine
preadipocytes cell lines Ob1771 and 3T3-F442A [31]. However,
it should be noted that the effect of exogenously added arachidonic
acid in the commonly used 3T3-L1 cell differentiation model
depends on the simultaneous presence of a cAMP-elevating agent
[6,26].
Most intracellular effects of cAMP are mediated by the protein
kinase A (PKA) [32] and the exchange protein directly activated
by cAMP (Epac), a guanine nucleotide exchange factor activated
by cAMP [33,34]. The Epac protein family comprises two main
isoforms, Epac1 and Epac2, which are also known as RAPGEF3
and RAPGEF4, respectively. Each contains a functional cAMP-
binding domain and a guanine nucleotide-exchange factor
domain, which activates the small GTPase Rap1 in response to
cAMP [35,36]. The functional analysis of Epac was greatly
facilitated by the development of the cAMP analog 8-pCPT-29O-
Me-cAMP, which binds specifically to Epac1 and Epac2 with no
significant activation of other cAMP targets, i.e. PKA and ion
channels [37]. Epac has been implicated in the regulation of
several important biological functions, including insulin secretion,
cell adhesion, neural differentiation, proliferation and ion
transport [38,39]. Rho GTPases are essential components of the
signaling pathway that directs reorganization of the actin
cytoskeleton. The action of Rho is mediated by the downstream
effector, Rho-associated kinase (ROCK) [40,41]. Rho A and
ROCK have been shown to play pivotal roles during commitment
of MSCs by modulating cell shape and cytoskeletal tension
[42,43].
We have recently reported that Epac via Rap1 and PKA
synergistically promote adipogenesis of 3T3-L1 cells [44]. We
provided evidence that Epac activation promotes adipocyte
differentiation by counteracting the decrease in IGF-1/insulin
signaling mediated via an efficient PKA-dependent inhibition of
Rho/ROCK activity [45]. Accordingly, we demonstrated that
Epac activation was sufficient to enhance adipocyte differentiation
when ROCK was inhibited.
In contrast to the situation prevailing in mouse preadipocytes,
the role of Epac for induction of adipocyte differentiation of
human adipocyte precursor cells is still poorly understood. In the
present study we demonstrate that adipocyte differentiation in vitro
of human mesenchymal stem cells derived from adipose tissue
(hMADS cells), is critically dependent of cAMP signaling requiring
activation of both the PKA and the Epac branch of signaling.
Furthermore, consistent with the results obtained with the murine
3T3-L1 cells, selective activation of Epac robustly induced
adipocyte differentiation of hMADS cells when ROCK activity
was inhibited. Of note, and contrasting murine preadipocytes,
effective differentiation of hMADS cells even in the presence of the
powerful PPARc agonist rosiglitazone required inclusion of a
cAMP elevating agent. We evaluated thoroughly the effects of
PPAR agonists and various fatty acids on adipocyte differentiation
of hMADS cells. Contrasting previous observation using murine
preadipocytes, none of the tested fatty acid, including arachidonic
acid, promoted adipocyte differentiation of hMADS cells.
Interestingly, we found that prolonged treatment with the
synthetic PPARd agonist L165041 also promoted adipocyte
differentiation of hMADS cells in the presence of the cAMP
elevating agent isobutylmethylxanthine (IBMX). Taken together
our results emphasize the need for cAMP signaling in concert with
treatment with a PPARc or PPARd agonist to secure efficient
adipocyte differentiation of human hMADS mesenchymal stem
cells.
Results
Elevated levels of cAMP promote adipocyte
differentiation of hMADS cells
To determine whether elevated levels of intracellular cAMP also
are required to promote adipocyte differentiation of hMADS cells,
two-days-post-confluent hMADS cells were treated with the
adipogenic cocktail with or without a cAMP elevating agent.
Oil-Red-O staining and adipocyte marker gene expression clearly
demonstrated that elevation of cAMP levels by addition of the
phosphodiesterase inhibitor IBMX or the cell-permeable cAMP
analog 8-pCPT-cAMP strongly enhanced adipocyte differentia-
tion. In the absence of elevated levels of cAMP only very few
preadipocytes underwent differentiation even in the presence of
the strong inducers of adipocyte differentiation, insulin, dexa-
methasone (Dex) and rosiglitazone (Fig. 1A and 1B).
The adipogenic effect of cAMP requires the activation of
both PKA- and Epac-dependent signaling pathways
We have recently demonstrated that cAMP-stimulated differ-
entiation of murine 3T3-L1 cells into adipocytes in vitro requires
Epac/Rap signaling [44]. Given the importance of a cAMP-
elevating agent during differentiation of hMADS cells in serum-
free conditions, we sought to determine the requirement of Epac/
Rap in these human cells. Real-time qPCR analyses demonstrated
that both RAPGEF3 (Epac1) and RAPGEF4 (Epac2) mRNA were
expressed in hMADS cells (Fig. 2A). Expression of RAPGEF3
mRNA, the predominant isoform, transiently decreased after
induction of differentiation, followed by increased expression on
day 4. After day 4, RAPGEF3 mRNA level declined gradually to
barely detectable levels in mature adipocytes (day 14). By contrast,
expressions of RAP1A and RAP1B mRNA (the dominant Rap
isoforms in hMADS cells) were higher in mature adipocytes than
in undifferentiated cells (Fig. 2B). Having established that Epac and
RAP1 are expressed in hMADS cells, we tested whether the
selective Epac-activating cAMP-analog 8-pCPT-29-O-Me-cAMP
(007), alone or in combination with the selective PKA-activating
analog 6-MB-cAMP (MB), could mimic the effect of IBMX in
stimulating adipogenesis. In accordance with results obtained in
murine preadipocytes [44], addition of 007 or MB alone only
slightly enhanced adipocyte differentiation of hMADS cells.
However, as demonstrated by Oil-Red-O staining, a majority of
the cells rounded up to become lipid-filled adipocytes when treated
with both 007 and MB (Fig. 3A). The robust induction of
adipocyte marker genes mRNAs (Fig. 3B) and proteins (Fig. 3C) in
cells treated with both 007 and MB confirmed the adipocyte
phenotype. The selectivity of 007 and MB on Epac and PKA
activation, respectively, was confirmed by measurement of Rap
activation and fractional PKA activity. As predicted, treatment of
hMADS cells with 007, but not MB, led to activation of Rap1 as
cAMP Signaling in Differentiation of hMADS Cells
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determined by increased levels of GTP-loaded Rap1 (Fig. 3D). Vice
versa, treatment of the hMADS cells with MB alone or in
combination with 007 increased fractional PKA activity, whereas
007 alone had no effect (Fig. 3E). We further assessed the effects of
the PKA-specific inhibitors, the cAMP analogs Rp-8-CPT-cAMPS
and Rp-8-Br-cAMPS (Rps) [37,44] on adipocyte differentiation of
hMADS cells induced by DI+007+MB (Fig. S1). Addition of Rps
decreased the triglyceride content in the cells (Fig. S1A) and
significantly reduced the induction of adipocyte marker genes
mRNAs (Fig. S1B), emphasizing the importance for PKA activity
for adipocyte differentiation of hMADS cells. Together, these
results indicate that the adipogenic effect of cAMP requires both
Epac and PKA activity in hMADS cells.
Epac1 is required for isobutylmethylxanthine-induced
adipogenesis of hMADS cells
To substantiate the importance of Epac in 007-mediated Rap-
activity in hMADS cells, we transduced hMADS cells with a
retroviral vector expressing a dominant negative Epac1 (dnEpac1)
or an empty vector. As predicted, 007 failed to activate Rap1 in
cells expressing dnEpac1, but increased the levels of GTP-
associated Rap1 in cells transduced with the empty vector
(Fig. 4A). To further corroborate the importance of Epac1 in
cAMP-stimulated adipose conversion, hMADS cells expressing
dnEpac1 or the empty vector were induced to differentiate by the
hormonal differentiation cocktail including IBMX. As shown in
Fig. 4B, hMADS cells expressing dnEpac1 did not accumulate
lipids, whereas cells expressing the empty vector rounded up and
accumulated lipids as evidenced by Oil-Red-O staining. The lack
of an adipogenic phenotype in cells expressing the dnEpac1 was
verified by real-time PCR analysis demonstrating a significantly
reduced expression of adipogenic markers compared to cells
expressing the empty vector (Fig. 4C). Taken together, these
results demonstrate that Epac1 signaling is required for IBMX
induced adipogenesis of hMADS cells.
Epac activation enhances adipocyte differentiation of
hMADS cells when ROCK is inhibited
In murine preadipocytes Epac activation promotes adipocyte
differentiation by counteracting the decrease in IGF-1/insulin
signaling mediated via the PKA-dependent inhibition of Rho/
ROCK activity [44]. To examine if the same mechanism operates
in hMADS cells, we treated hMADS cells with the ROCK
inhibitor Y-27632 [42] in the presence or absence of 007. As
shown in Fig. 5, administration of Y-27632 in the presence of Dex
did not stimulate adipogenesis. Similarly, treatment with the Epac
activator 007 in the presence of Dex did not promote adipogenesis.
However, treatment of hMADS cells with Y-27632 in combina-
tion with 007 significantly enhanced adipocyte differentiation, as
demonstrated by both Oil Red O staining and adipocyte marker
genes expression (Fig. 5A and B).
Figure 1. A cAMP elevating agent is required for adipocyte
differentiation of hMADS cells. (A) Two-day post-confluent hMADS
cells were induced to differentiate with 1 mM Dex and 0.86 mM insulin
(DI) in the presence or absence of 0.5 mM IBMX, 100 mM 8-pCPT-cAMP
or an equal volume of water (vehicle) from day 0 to day 3. Thereafter,
0.5 mM rosi was added until day 9. On day 14, cells were fixed, and
cytoplasmic triglycerides were stained with Oil-Red-O. Undifferentiated
hMADS cells were used as control. The photographs and micrographs
shown are representative of 3 independent experiments. (B) RNA was
isolated on day 14, and expression of PPARG2, CEBPA, FABP4 and LPL
was determined by RT-qPCR. Data presented were normalized to the
value of DI treated cells. Significant differences relative to DI treated
cells are indicated by asterisks, *p,0.05, **p,0.01, ***p,0.001, n = 6.
doi:10.1371/journal.pone.0034114.g001
Figure 2. Expression of Epac and Rap mRNAs in hMADS cells.
Cells were differentiated as described in ‘‘Materials and Methods’’. RNA
was isolated on the indicated days. The levels of RAPGEF3 (Epac1),
RAPGEF4 (Epac2) mRNAs (A) and RAP1A, RAP1B, RAP2A, RAP2B, RAP2C
mRNAs (B) were determined by RT-qPCR. Data presented in (A) were
normalized to RAPGEF3 on day 0; in (B) data were normalized to RAP1B
on day0. Significant differences are indicated by asterisks, *p,0.05,
**p,0.01, ***p,0.001, n = 8.
doi:10.1371/journal.pone.0034114.g002
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Effects of PPARs agonists and long-chain fatty acids on
adipocyte differentiation of hMADS cells
PPARs play critical roles in the development and metabolic
regulation of adipose tissue, and the cAMP-dependent synthesis of
endogenous PPARc ligand(s) has been shown to be crucial during
the initial stage of adipocyte differentiation of murine preadipo-
cytes [26,45]. To initially characterize the possible temporal
contribution of the different PPAR isoforms, including PPARa
and PPARd, in adipogenesis, we treated two day-post-confluent
hMADS cells (defined as day 0) with the hormonal cocktail
including dexamethasone, IBMX and insulin in the absence or
presence of selective PPAR activators for different periods of time.
To monitor adipocyte differentiation we measured the increase in
glycerol-3-phosphate dehydrogenase (GPDH) activity on day 14.
GPDH is, a robust indicator of adipocyte differentiation and
required for triglyceride synthesis [46]. As expected, treatment
with rosiglitazone stimulated a robust increase in GPDH activity
(Fig. 6). Treatment with rosiglitazone during the initial stage of
differentiation, i.e. during day 0–3 was sufficient to elicit a robust
increase in GPDH activity, which only increased slightly by
prolonged treatment. Furthermore, treatment with rosiglitazone
Figure 3. Adipocyte differentiation of hMADS cells requires the activation of both Epac- and PKA-dependent signaling pathways.
Two-day post-confluent hMADS cells were induced to differentiate with 1 mM Dex, 0.86 mM insulin (DI), in the presence of 200 mM of the Epac-
selective cAMP analog 8-pCPT-29-O-Me-cAMP (007) [37], 100 mM of PKA selective cAMP analog 6-MB-cAMP (MB) [37], either separately or in
combination (007+MB) from day 0 to day 3. Rosi (0.5 mM) was present from day 3–9. Undifferentiated hMADS cells were taken as control. (A) The
panel shows cells on day 14 stained with Oil-Red-O. The photographs and micrographs shown are representative of 3 independent experiments.
(B) RNA was isolated on day 14, and expression of PPARG2, CEBPA, FABP4 and LPL was determined by RT-qPCR. Date presented were normalized to
the value of DI treated cells. Significant differences are indicated by asterisks, *p,0.05, **p,0.01, ***p,0.001, n = 9. (C) Whole cell extracts were
prepared and analyzed for FABP4 protein level by Western blotting. (D and E) Two-day post-confluent hMADS cells were treated for 15 min with
200 mM 8-pCPT-29-O-Me-cAMP (007) or 100 mM 6-MB-cAMP (MB) or an equal volume of water (vehicle) in medium with Dex and Insulin. (D) GTP
bound RAP1 was measured by a RAP1 activation pull-down assay as described in ‘‘Materials and Methods’’. (E) PKA activity in cell lysates was
determined as described in ‘‘Materials and Methods’’. Significant differences relative to DI treated cells are indicated by asterisks, *p,0.05, **p,0.01,
***p,0.001, n = 4.
doi:10.1371/journal.pone.0034114.g003
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from day 3–14 also induced robust differentiation as determined
by the increased GPDH activity. A weak differentiation was
observed in cells treated with the PPARa agonist Wy14643
regardless of the exposure time. By contrast, in murine
preadipocytes treatment with PPARa agonists elicits a robust
induction of adipocyte differentiation [20], a difference that may at
least in part relate to the different affinity of the agonist with
respect to mouse and human PPARa [47,48]. Of note, cells
treated chronically with the PPARd agonist L165041 also
exhibited high levels of GPDH activity (Fig. 6A). Whether this
reflected the ability of L165041 to function as a weak PPARc
agonist or whether activated PPARd was able to induce expression
of PPARc in human cells as described for murine preadipocytes
[22,49] remains to be elucidated. However, the fact that treatment
with L165041 during the first three days of the differentiation
process did not induce adipocyte differentiation similar to
treatment with the selective PPARc agonist rosiglitazone indicates
that L165041 did not promote adipocyte by direct activation of
PPARc. Collectively, these results indicate that both PPARc and
PPARd agonists promote adipocyte conversion of hMADS cells
consistent with the expression of their cognate receptors in
confluent undifferentiated hMADS cells [50].
Long-chain fatty acids and a plethora of oxygenated fatty acid
derivatives bind to and activate the three members of the PPAR
family [23,27,29,30] and promote adipocyte differentiation of
murine preadipocytes [11]. We tested the ability of a series of long-
chain fatty acids to promote adipogenesis of hMADS cells in the
presence of the adipogenic inducers dexamethasone, IBMX and
insulin. None of the tested fatty acids promoted adipocyte
differentiation of hMADS cells as determined by GPDH activity
(Fig. 6B). Arachidonic acid can serve as a substrate for cAMP-
dependent generation of PPARc ligands [24,25,45]. The n-6
PUFA arachidonic acid has further been shown to promote
adipocyte differentiation of murine Ob1771 preadipocytes [13] via
Figure 4. Dominant negative Epac1 attenuates adipocyte differentiation of hMADS cells. hMADS cells were infected with retroviruses
expressing a dominant-negative form of Epac1 (dnEpac1) or an empty vector and grow to confluence. (A) GTP-bound Rap1 was measured by a Rap1
activation pull-down assay. (B) Cells were induced to differentiate with Dex, insulin, IBMX and Rosi as described in ‘‘Materials and Methods’’. On day
14, cells were stained with Oil-Red-O and photographed. The photographs and micrographs shown are representative of 4 independent experiments.
(C) PPARG2, CEBPA, FABP4 and LPL mRNA levels were determined by RT-qPCR. Expression was normalized to cells transduced with empty vector.
Significant differences are indicated by asterisks, **p,0.01, ***p,0.001, n = 6.
doi:10.1371/journal.pone.0034114.g004
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a cyclooxygenase-dependent conversion into PGI2 which by
binding to the PGI2 receptor, IP-R, enhances cAMP production
[13,26,31]. However, addition of arachidonic acid did not
promote adipocyte differentiation of hMADS in the presence of
IBMX, suggesting that arachidonic acid-dependent ligand pro-
duction is absent or too limited in hMADS cells to support
adipocyte differentiation and/or the addition of arachidonic acid
in combination with a cAMP elevating agent led to the production
of inhibitory prostaglandins as previously observed for 3T3-L1
cells [6,26]. Furthermore, arachidonic acid was unable to
substitute for IBMX and promote adipocyte differentiation of
hMADS cells treated with DEX, insulin and rosiglitazone (Fig. 6C).
Interestingly, even low concentrations of carbaprostacyclin (cPGI),
a stable analog of PGI2, rescued adipocyte differentiation of
hMADS cells in the absence of IBMX suggesting that PGI2
synthesis, release or action on IP-R is impaired in hMADS cells
(Fig. 7). The results shown in Fig. 7 also demonstrate the
requirement for dexamethasone to support adipocyte differentia-
tion of hMADS cells. Taken together these results emphasize the
need for cAMP signaling in concert with treatment with a PPARc
or PPARd agonist to secure efficient adipocyte differentiation of
human hMADS mesenchymal stem cells.
Discussion
Adipose tissue-derived stem cells are a promising source of
human stem cells for regenerative medicine because of their
convenient isolation and extensive proliferative capacities in vitro.
Identifying the molecular cues and regulators that drive differen-
tiation in vitro is crucial for therapeutic use of these cells. hMADS
cells are multipotent stem cells established from the stromal-
vascular fraction of infant adipose tissue. These cells can be
differentiated into adipocytes under serum free, chemically defined
conditions. Moreover, once differentiated, hMADS cells are like
human adipocytes able to secrete leptin and adiponectin [51]. As
hMADS cells also express the various components involved in fatty
acid metabolism and exhibit a lipolytic capacity similar to that of
human adipocytes [52], these features underscore the utility of
hMADS to serve as a good model for studying molecular
mechanisms of adipocyte differentiation and functions.
cAMP signaling pathways are known to regulate a wide array of
cellular processes by acting through its downstream effectors
proteins PKA and Epac, and several studies have clearly
demonstrated that the cAMP/PKA and cAMP/Epac pathways
coexist in cells and function independently, but impinge on
common molecular targets [35,38,53,54]. However, the role of
Epac in human adipocytes is still poorly understood. In the present
study, we provide evidence that cAMP/PKA and cAMP/Epac
pathways synergistically promote adipocyte differentiation of
hMADS cells. Neither activation of PKA alone by 6-MB-cAMP
nor activation of Epac by 8-pCPT-29-O-Me-cAMP induced
significant differentiation. However, when these two compounds
were combined, differentiation was strongly enhanced. Inhibition
of endogenous Epac1 activity by transfection with a dominant
negative version of Epac1, dnEpac1, strongly attenuated the pro-
adipogenic effect of cAMP. Similarly, like in murine preadipo-
cytes, Epac activation enhanced adipocyte differentiation of
hMADS cells in the presence of a ROCK inhibitor. Collectively,
our results provide evidence that activation of both PKA- and the
Epac-dependent pathways are necessary to promote adipocyte
differentiation of hMADS cells. Contrasting murine preadipocytes,
hMADS cells requires the addition of a PPARc agonist for
differentiation indicating that synthesis of endogenous PPARc
ligand(s) is insufficient to trigger adipogenesis in vitro. Of note, even
in the presence of the powerful adipogenic inducers insulin,
Figure 5. Effects of ROCK inhibitor Y-27632 on adipocyte differentiation of hMADS cells. Two-day post-confluent hMADS cells were
induced to differentiate with 1 mM Dex in the presence of 200 mM 007, 10 mM Y-27632 either separately or in combination from day 0 to day 3. At the
same time, another group of cells were treated with 1 mM Dex, 0.86 mM insulin (DI) in the presence of 200 mM 8-pCPT-29-O-Me-cAMP (007) and
100 mM 6-MB-cAMP (MB). From day 3 to day 9, the medium contained 0.5 mM Rosi and 0.86 mM insulin. The medium was changed every second day.
On day 14, (A) cells were stained by Oil Red O and photographed; (B) Total RNA was isolated and the expression of PPARG2, CEBPA, FABP4 and LPL was
determined by RT-qPCR. Expression was normalized to the value of Dex treated cells. Significant differences are indicated by asterisks, *p,0.05,
**p,0.01, ***p,0.001, n = 9.
doi:10.1371/journal.pone.0034114.g005
cAMP Signaling in Differentiation of hMADS Cells
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e34114
Figure 6. Effects of PPAR agonists and long-chain fatty acids on adipocyte differentiation of hMADS cells. Two-day post-confluent
hMADS cells were maintained in serum-free DMEM/Ham’s F12 medium in the presence of 1 mM Dex, 0.5 mM IBMX, and 0.86 mM insulin. From day 3,
the medium consisted of DMEM/Ham’s F12 with 0.86 mM insulin and was changed every second day. In addition, (A) 0.5 mM PPARc agonist
rosiglitazone (Rosi), 0.5 mM PPARd agonist L165041, or 20 mM PPARa agonist Wy14643 was added for the indicated time periods; Significant
differences relative to control are indicated by asterisks, ***p,0.001, n = 6. (B) Rosi, n-6 arachidonic acid (ARAn6), n-3 arachidonic acid (ARAn3),
docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), linoleic acid (LA), a-linoleic acid (LNA), oleic acid (Ole), and palmitic acid (Palm) dissolved in
DMSO were added at the indicated concentrations from day 3 to day 9. GPDH activities were determined on day 14. In panel B, data presented were
cAMP Signaling in Differentiation of hMADS Cells
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dexamethasone and rosiglitazone, efficient differentiation of
hMADS cells still requires elevated intracellular levels of cAMP.
To further investigate the role of PPAR activation and the
ability of various fatty acids to promote adipocyte differentiation of
hMADS cells, we treated post-confluent hMADS cells with
selective activators of PPARa, PPARd and PPARc. The PPARc
agonist rosiglitazone elicited a strong adipogenic response.
Incubation with the PPARa agonist Wy14643 supported a modest
increase in adipocyte differentiation as determined by GPDH
activity, contrasting the situation in murine preadipocytes where
PPARa agonists powerfully induce adipocyte differentiation [20].
A difference in binding affinity between human and murine
PPARa may in part explain this difference [47,48]. Recently,
treatment of hMADS cell with the potent PPARa agonist
GW7647 was shown to enhance fatty acid oxidation and GPDH
activity, underscoring the possibility that differences in affinity may
at least in part explain the lack of effect of Wy14643 on hMADS
cells [55]. Of note, sustained incubation with the PPARd agonist
L165041 resulted in adipocyte differentiation to the same degree
as incubation with rosiglitazone. Activation of PPARd has been
shown to induce expression of PPARc in murine preadipocytes,
and a similar mechanism may operate in the human hMADS cells.
Once PPARc expression has reached a certain threshold,
stimulation of adipocyte differentiation may occur ligand-inde-
pendent [24,56]. However, it should be noted that whereas
simultaneous administration of a PPARd-selective ligand and
IBMX significantly enhanced clonal expansion and the early
expression of PPARc in murine 3T3-L1 preadipocytes, this
treatment only modestly promoted terminal differentiation [20].
Thus, the robust differentiation of hMADS cells treated with
IBMX and a PPARd agonist is remarkable and warrants further
investigation.
Long-chain fatty acids have been shown to exhibit an
adipogenic activity at least in part by activating PPARc and
PPARd in murine preadipocytes in the absence of agents that
elevates the intracellular levels of cAMP. In particular arachidonic
acid has been shown to be adipogenic in conditions with low
intracellular levels of cAMP, but also other n-6 PUFAs and n-3
PUFAs promote adipocyte differentiation of 3T3-L1 preadipocytes
when the intracellular level of cAMP is low [6,26,57]. Arachidonic
acid plays an additional role by giving rise to PGI2 via the
cyclooxygenase pathway. After release from the cells PGI2
promotes differentiation of the murine preadipocytes by binding
to the PGI2 receptor, IP-R, stimulating cAMP production
[13,26,31]. In contrast to the effect on murine preadipocytes,
none of these fatty acids promoted adipocyte differentiation of
hMADS cells in the presence of a cAMP elevating agent.
Furthermore, arachidonic acid was unable to substitute for IBMX
and promote adipocyte differentiation of hMADS cells treated
with DEX, insulin and rosiglitazone (Fig. 6C). The finding that
addition of carbaprostacyclin (cPGI) a stable analog of PGI2
rescued adipocyte differentiation of hMADS cells in the absence of
IBMX, but in the presence of insulin and rosiglitazone, indicates
that insufficient amounts of PGI2 are synthesized by hMADS cells
or PGI2-dependent signaling is abrogated even with addition of
exogenous arachidonic acid despite the fact that IP-R, COX1 and
COX2 are expressed in confluent hMADS cells (E.-Z. Amri;
unpublished observation). Alternatively, arachidonic acid or other
PUFAs may in hMADS cells be converted into prostanoids that
inhibit adipocyte differentiation [6,26,57,58]. Because addition of
arachidonic acid did not rescue differentiation in the absence of a
PPARc ligand, this also indicates that hMADS cells have an
insufficient capacity for producing endogenous PPARc ligands
from arachidonic acid.
In conclusion, our results demonstrate a pivotal role of cAMP
signaling during initiation of adipocyte differentiation of hMADS
cells requiring both PKA- and Epac-dependent signaling. cAMP
signaling has been shown to induce production of endogenous
PPARc ligand(s) in murine preadipocytes [24–26,45]. By contrast,
whereas cAMP signaling is also required for differentiation in
human mesenchymal hMADS cells, it does not induce sufficient
synthesis of PPARc ligand(s) to promote adipocyte differentiation
even in presence of fatty acids that can serve as precursors for
synthesis of PPARc ligands. In 3T3-L1 cells, cAMP-dependent
activation of PKA increases the activity of PPARd promoting the
early stages of adipocyte differentiation, but not terminal
differentiation [22]. By contrast, combined treatment of hMADS
cells with IBMX and a PPARd agonist robustly induced terminal
adipocyte differentiation. Furthermore, activated PKA also
represses Rho-kinase activity, which allows adipocyte differentia-
tion [44]. Finally, arachidonic acid, which in murine preadipocytes
can enhance cAMP production via synthesis of PGI2, is unable to
replace the addition of a cAMP-elevating agent in hMADS cells
(Fig. 7). The fact that addition of the stable PGI2 analog
carboprostacyclin (cPGI) rescued adipocyte differentiation in the
normalized to Rosi treated cells. Significant differences relative to Rosi are indicated by asterisks, ***p,0.001, n = 6. C) Two-day post-confluent
hMADS cells were maintained for 3 days in serum-free DMEM/Ham’s F12 medium in the presence of 1 mM Dex and 0.86 mM insulin supplemented
with either 0.5 mM IBMX or various fatty acids as indicated. From day 3 to day 9, 0.5 mM Rosi was then added and GPDH activities were determined
on day 14. Significant differences relative to IBMX-treated cells are indicated by asterisks, **p,0.01, ***p,0.001, n = 6.
doi:10.1371/journal.pone.0034114.g006
Figure 7. Carbaprostacyclin rescues adipocyte differentiation
in the absence of other cAMP elevating agents. Two-day post-
confluent hMADS cells were maintained in induction media with
0.86 mM insulin in the presence or absence of 1 mM Dex, 0.5 mM IBMX
or 0.2 or 1 mM carbaprostacyclin (cPGI) as indicated from day 0 to day 3.
Thereafter, 0.5 mM rosiglitazone was added until day 9. GPDH activities
were determined on day 14.
doi:10.1371/journal.pone.0034114.g007
r
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absence of other cAMP-elevating agents points to impaired PGI2
synthesis, secretion and/or signaling via the PGI2 receptor in
hMADS cells, further underscoring the difference between the
human and the murine systems.
Materials and Methods
Chemicals
The cAMP analogs were purchased from Biolog (Bremen,
Germany). All the other chemicals, except where specified were
purchased from Sigma-Aldrich.
Cell Culture and Differentiation
The establishment and characteristics of human multipotent
adipose-derived stem (hMADS) cells have been described
[17,51,59,60]. Briefly, in the present study hMADS-2 cells were
established from the pubic region fat pad of a 5-year old male
donor after informed consent of the parents, and used between 16
and 35 passages corresponding to 35 to 100 population doublings.
The protocol was approved by the Centre Hospitalier Universi-
taire de Nice Review Board.
hMADS cells were routinely cultured in Dulbecco’s modified
Eagle’s medium (DMEM) (Lonza, Denmark) supplemented with
10% (v/v) fetal bovine serum (FBS), 2.5 ng/ml hFGF2 (Invitro-
gen), 60 mg/ml penicillin, and 50 mg/ml streptomycin, at 37uC in
a humidified atmosphere containing 5% CO2. Medium was
changed every other day. For adipogenic differentiation, hFGF2
was removed when cells reached confluence. Two-days-post-
confluent (designated as day 0) cells were induced to differentiate
in the presence of DMEM/Ham’s F12 media (Lonza, Denmark)
supplemented with 10 mg/ml transferrin, 0.2 nM triiodothyro-
nine, 0.86 mM insulin, and 1 mM dexamethasone (Dex), 0.5 mM
isobutylmethylxanthine (IBMX). After two days, the medium was
changed (Dex and IBMX omitted), and 0.5 mM rosiglitazone
(Novo Nordisk A/S, Denmark) was added. The media were then
changed every other day and cells were harvested as indicated. 8-
pCPT-cAMP (100 mM), 8-pCPT-29-O-Me-cAMP (200 mM) (007),
6-MB-cAMP (100 mM) (MB), Rp-8-CPT-cAMPS (100 mM), Rp-8-
Br-cAMPS (100 mM), carbaprostacyclin (0.2 or 1 mM)(cPGI)(Cay-
man Chemical, France), L165041 (0.5 mM)(Tocris Bioscience,
France), Wy14643 (20 mM)(Cayman Chemical, France) and
different fatty acids (3 or 10 mM in the presence of 1.5 or 5 mM
human serum albumin) were added at the time stated in the legend
of figures.
For Oil Red O Staining, cells were washed with PBS, fixed with
3.7% (w/v) formaldehyde for 1 h, rinsed twice with water, then
stained for 1 h with Oil Red O [61]. After staining, cells were
washed twice with water and photographed. Glycerol-3-phosphate
dehydrogenase (GPDH) activities, a robust indicator of adipocyte
differentiation required for triglyceride synthesis, were measured
as described previously [54].
Retroviral transduction
The dominant-negative Epac1 cDNA was kindly provided by
Dr. Johannes L. Bos. pLXSN-hygro was kindly provided by Dr.
O. A. MacDougald. The retroviral vectors encoding dominant-
negative Epac1 (pLXSN-dnEpac1) has been described before
[44,62]. For transfection, phoenix-Ampho cells at 50% confluence
were transfected with emptry vector (pLXSN) or pLXSN-dnEpac1
vector DNA using a standard calcium phosphate protocol. 48 h
after transfection, virus supernatant were collected by centrifuga-
tion and filtered. Fifty percent confluent hMADS cells were
transduced with virus supernatant diluted with one volume of fresh
growth medium and 8 mg/mL polybrene. The following day, one
successive cycle of transduction was performed to enhance the
transduction efficiency. After that, cells were split and subjected to
hygromycin B selection (400 mg/mL) (Calbiochem). After approx-
imately 10 days, the selected clones were pooled and replated for
differentiation.
Real Time RT-PCR
Total RNAs were purified from cells using Trizol reagent
(Invitrogen). 1 mg of total RNA, digested with RQ1 Dnase
(Invitrogen), was reverse transcribed using MMLV reverse
transcriptase (Invitrogen) and random hexamers (Amersham
Pharmacia Biotech) at 37uC for 1 h. After cDNA synthesis,
reactions were diluted with 50 mL of water and frozen at 280uC.
Real-time quantitative PCR (qPCR) was performed in 20 mL
reactions containing SYBR Green Mastermix, 1.5 mL of diluted
cDNA and 300 nM of each primer using an Mx3000P real-time
PCR instrument (Stratagene). Reaction mixtures were preheated
at 95uC for 10 min, followed by 40 cylcles of 95uC for 15 s and
60uC for 30 s. PCR was carried out in 96-well plates and in
duplicate. Primers were designed using Primer Experss 2.0
(Applied Biosystems) and the sequences are listed in Table S1 in
supporting information. Target gene mRNA expression was
normalized to the expression level of and endogenous house-
keeping gene beta-2-microglobulin (B2M).
Whole cell extracts and Western Blotting
Whole cell lysates were prepared in SDS sample buffer as
described before [61]. Protein content was measured by Bradford
method (Bio-Rad). Equal amount of protein was loaded for
electrophoresis and proteins were transferred onto PVDF
nitrocellulose membranes (Millipore). Equal loading/transfer was
confirmed by Amido Black staining of membranes. Membranes
were blocked for 1 h in TBS containing 5% nonfat dry milk.
Incubation with primary and secondary antibodies was performed
in TBS containing 5% nonfat dry milk for 1 h. Membranes were
then washed in TBS and signals were visualized with enhanced
chemiluminescence (ECL). The primary antibodies used were
rabbit anti FABP4/aP2 antibody (Caymen Chemical) and mouse
anti vimentin antibody (DAKO, Denmark A/S). Secondary
antibody was horse-radish peroxidase-conjugated anti-rabbit or
anti-mouse antibodies obtained from DAKO.
Rap1 activation assays
Cells were stimulated for 15 min in medium with 200 mM 8-
pCPT-29-O-Me-cAMP or 100 mM 6-MB-cAMP or equal volume
of water (vehicle) in the presence of Dex (1 mM) and insulin
(0.86 mM). Then cells were lysed in Rap1 activation lysis buffer.
Rap1 activation assays were performed in accordance with the
protocol of the Rap1 activation assay kit (Upstate). Briefly, lysate
was clarified by centrifugation and a portion of the cell lysate was
reserved for analysis for total Rap1 content. 500 mL lysate were
incubated with GST-tagged RBD of RalGDS pre-coupled to
glutathione beads to specially pull down the GTP-bound form of
Rap1. The proteins were eluted with SDS sample buffer and
analyzed by SDS-PAGE and Western blotting using Rap1
antibodies (Upstate).
Determination of PKA activity in cell lysates
Cells were stimulated for 15 min with 200 mM 8-pCPT-29-O-
Me-cAMP/100 mM 6-MB-cAMP or equal volume of water in
media containing Dex (1 mM) and Insulin (0.86 mM). Cells were
washed in ice-cold phosphate-buffered saline, and lysed in 0.5 ml
of 50 mM potassium phosphate buffer (pH 7.0) with 1 mM
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EGTA, 0.3 mM EDTA, 2 mM 1,4-dithioerythriol (DTE), 0.15%
Triton X-100, and Complete protease inhibitor cocktail (Roche).
Lysates were snap-frozen in liquid nitrogen and thawed immedi-
ately before the assay of kinase activity as described previously
[44]. The blank value was determined by incubating in the
presence of 100 nM of the inhibitor peptide from the heat-stable
PKA inhibitor.
Statistics
All experiments were performed in duplicate or triplicate and
repeated three or four times. The data are presented as means 6
S.D. Analysis of variance was performed by two-tailed Student’s t
test. Differences were considered statistically significant when p
was,0.05.
Supporting Information
Figure S1 Effects of PKA inhibitors on adipocyte
differentiation of hMADS cells. Two-day post-confluent
hMADS cells were maintained in induction media with 0.86 mM
insulin, 1 mM Dex, 200 mM 8-pCPT-29-O-Me-cAMP (007) and
100 mM 6-MB-cAMP (MB) in the presence or absence of 100 mM
Rp-8-CPT-cAMPS and 100 mM Rp-8-Br-cAMPS (Rps) as
indicated from day 0 to day 3. From day 3 to day 9, the medium
contained 0.5 mM Rosi and 0.86 mM insulin. The medium was
changed every second day. On day 14, (A) Cells were stained by
Oil Red O and photographed; (B) Total RNA was isolated and the
expression of PPARG2, CEBPA, FABP4 and LPL was determined
by RT-qPCR. Expression was normalized to the value of
DI+007+MB treated cells. Significant differences are indicated
by asterisks, *p,0.05, **p,0.01, ***p,0.001, n= 9.
(TIF)
Table S1 List of real-time RT-PCR primer sequences.
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